Form 4: STERIS Director Sells Shares, Receives New Equity
Insider Transaction Report
STERIS plc Director Cynthia L. Feldmann exercised stock options and sold shares, while also receiving new stock options and restricted stock units.
Summary
- Cynthia L. Feldmann, a Director of STERIS plc, engaged in multiple equity transactions.
- On August 11, 2025, she exercised 3,495 stock options with an exercise price of $114.74 per share.
- Concurrently, she sold 3,495 ordinary shares at a weighted average price of $241.56 per share, with individual sales ranging from $241.38 to $241.705.
- On August 8, 2025, Ms. Feldmann was granted 1,407 new Director Stock Options with an exercise price of $242.85 per share, which are immediately vested and exercisable, expiring on August 8, 2035.
- She also received 487 Career Restricted Stock Units (RSUs) on August 8, 2025, which are fully vested immediately and will be settled in STERIS ordinary shares six months after her cessation of Board service.
- Following these transactions, Ms. Feldmann directly holds 705 ordinary shares and indirectly holds 8,663 ordinary shares through the Cynthia L. Feldmann Revocable Trust.
- Her total beneficial ownership of derivative securities includes 1,407 Director Stock Options and 8,128 Career Restricted Stock Units.
Sentiment
Score: 6
Explanation: The filing details routine insider transactions, including the exercise of existing stock options and the sale of shares, which is common for liquidity or tax planning. The simultaneous grant of new stock options and restricted stock units to the director is a positive sign of continued alignment with shareholder interests and ongoing compensation.
Positives
- Director Cynthia L. Feldmann received new equity grants, including 1,407 Director Stock Options and 487 Career Restricted Stock Units, aligning her interests with shareholders.
- The newly granted stock options and RSUs are fully vested immediately, providing immediate beneficial ownership.
- The exercise of options and sale of shares indicates the director is realizing value from previously granted equity, which is a normal part of compensation.
Negatives
- The sale of 3,495 ordinary shares by a director could be perceived as a slight negative, as it reduces direct insider ownership, though it is often for liquidity or tax purposes following an option exercise.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: The sale of shares by a director could be viewed neutrally or slightly negatively, but the new equity grants demonstrate continued alignment. The transaction itself is small relative to the company's market capitalization and unlikely to have a significant impact.
Key Dates
| Date | Description |
|---|---|
| 08/08/2025 | Date of grant for new Director Stock Options and Career Restricted Stock Units. |
| 08/09/2028 | Expiration date of the Director Stock Options that were exercised. |
| 08/11/2025 | Date of stock option exercise and subsequent sale of ordinary shares. |
| 08/12/2025 | Date the Form 4 was signed by the authorized representative. |
| 08/08/2035 | Expiration date of the newly granted Director Stock Options. |
Keywords
STERIS plc, STE, Cynthia L. Feldmann, SEC Form 4, insider trading, stock options, restricted stock units, RSU, share sale, director compensation, equity grants
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.